Literature DB >> 34046493

The Living with Pulmonary Fibrosis questionnaire in progressive fibrosing interstitial lung disease.

Jeffrey Swigris1, Katelyn Cutts2, Natalia Male3, Michael Baldwin3, Klaus B Rohr3, Donald M Bushnell2.   

Abstract

The Living with Idiopathic Pulmonary Fibrosis (L-IPF) questionnaire was developed with substantial input from patients with idiopathic pulmonary fibrosis (IPF) to assess symptoms and health-related quality of life (HRQoL). Because IPF is the prototypical chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype, we expanded applicability of the L-IPF by deleting the word "idiopathic", creating the L-PF (Living with Pulmonary Fibrosis) questionnaire, and then assessed its relevance among patients with progressive fibrosing ILDs in one-to-one interviews. Patients in the USA and Germany with any progressive fibrosing ILD other than IPF were asked about their disease and symptoms, completed the 44-item L-PF questionnaire (comprising two modules that assess symptoms and impacts of disease) and then answered a series of debriefing questions. Interviews were recorded, transcribed and coded for qualitative content analysis. 20 patients were interviewed, but time constraints meant not all were asked about all items. The most frequent diagnoses were rheumatoid arthritis-associated ILD (25%) and mixed connective tissue disease-associated ILD (20%). Almost all patients endorsed the symptoms assessed by the L-PF: shortness of breath (19 out of 20 patients), cough (19 out of 20) and fatigue (18 out of 20). Most patients endorsed impacts of progressive fibrosing ILD on activities of daily living, physical well-being, sleep, emotional well-being, and social aspects of their lives. Most patients had an overall positive impression of the Symptoms module and understood items as intended. All seven patients asked understood the items of the Impacts module. The L-PF contains concepts relevant and important to patients with progressive fibrosing ILD, and items are understood as intended.
Copyright ©The authors 2021. This version is distributed under the terms of the Creative Commons Attribution Licence 4.0.

Entities:  

Year:  2021        PMID: 34046493      PMCID: PMC8141833          DOI: 10.1183/23120541.00145-2020

Source DB:  PubMed          Journal:  ERJ Open Res        ISSN: 2312-0541


  4 in total

1.  Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures.

Authors:  Marlies Wijsenbeek; Maria Molina-Molina; Olivier Chassany; John Fox; Liam Galvin; Klaus Geissler; Katherine M Hammitt; Michael Kreuter; Teng Moua; Emily C O'Brien; Ashley F Slagle; Anna Krasnow; Matthew Reaney; Michael Baldwin; Natalia Male; Klaus B Rohr; Jeff Swigris; Katerina Antoniou
Journal:  ERJ Open Res       Date:  2022-05-03

2.  The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases.

Authors:  Surinder S Birring; Donald M Bushnell; Michael Baldwin; Heiko Mueller; Natalia Male; Klaus B Rohr; Yoshikazu Inoue
Journal:  Eur Respir J       Date:  2022-06-02       Impact factor: 33.795

Review 3.  The Burden of Progressive-Fibrosing Interstitial Lung Diseases.

Authors:  Vincent Cottin; Rhiannon Teague; Lindsay Nicholson; Sue Langham; Mike Baldwin
Journal:  Front Med (Lausanne)       Date:  2022-02-01

4.  Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases.

Authors:  Jeffrey J Swigris; Donald M Bushnell; Klaus Rohr; Heiko Mueller; Michael Baldwin; Yoshikazu Inoue
Journal:  BMJ Open Respir Res       Date:  2022-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.